Lantheus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LANTHEUS
LANTHEUS has seven approved drugs.
There are thirteen US patents protecting LANTHEUS drugs.
There are one hundred and thirty-five patent family members on LANTHEUS drugs in thirty-two countries and twenty-nine supplementary protection certificates in sixteen countries.
Summary for Lantheus
| International Patents: | 135 |
| US Patents: | 13 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 7 |
Drugs and US Patents for Lantheus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | 11,857,646 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lantheus Medcl | DEFINITY RT | perflutren | INJECTABLE;INTRAVENOUS | 021064-002 | Nov 17, 2020 | RX | Yes | Yes | 10,583,208 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | 11,925,695 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | 9,789,210 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lantheus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | 8,394,356 | ⤷ Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | 6,146,657 | ⤷ Start Trial |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | 5,362,475 | ⤷ Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | 5,527,521 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Lantheus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1841465 | ⤷ Start Trial |
| Singapore | 10201913353Y | ⤷ Start Trial |
| Hong Kong | 1244677 | ⤷ Start Trial |
| Spain | 2683818 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lantheus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0164843 | SPC/GB98/028 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: 153 SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONIC ACID (QUADRAMET); REGISTERED: CH CH 54265 19971006; UK EU/1/97/057/001 19980205 |
| 2213652 | PA2015005 | Lithuania | ⤷ Start Trial | PRODUCT NAME: FLORBETABENUM (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220 |
| 2213652 | CA 2015 00018 | Denmark | ⤷ Start Trial | PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140220 |
| 0806968 | SPC/GB07/011 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
